2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Appoints Thomas Copmann, Ph.D. as Vice President of Regulatory Affairs and Drug Development
February 27, 2015 09:00 ET | Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 27, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Announces $7 Million Private Placement of Common Stock
February 04, 2015 09:00 ET | Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 4, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc.(OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics and CureDuchenne to Host Webinar on January 21, 2015 at 3:00 p.m. ET
January 21, 2015 08:00 ET | Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure
January 12, 2015 12:32 ET | Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Announces $10 Million Private Placement of Common Stock
January 12, 2015 09:26 ET | Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray's 26th Annual Healthcare Conference
December 02, 2014 07:45 ET | Capricor Therapeutics, Inc.
LOS ANGELES, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Announces Favorable ALLSTAR Phase I Safety Results
November 18, 2014 08:00 ET | Capricor Therapeutics, Inc.
LOS ANGELES, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Announces Positive Pre-Clinical Data for Cardiosphere-Derived Cells (CDCs) on Duchenne Muscular Dystrophy Cardiomyopathy
November 18, 2014 07:45 ET | Capricor Therapeutics, Inc.
LOS ANGELES, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Reports Third Quarter 2014 Financial & Business Highlights
November 12, 2014 08:30 ET | Capricor Therapeutics, Inc.
Announced Plans for Cenderitide Clinical Program and Clinical Program for Duchenne Muscular Dystrophy Conference Call Scheduled for Wednesday, November 12, 2014 (4:30 p.m. EST) LOS ANGELES,...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics to Hold Duchenne Muscular Dystrophy Data Presentation Call on November 18, 2014 at 9:30 a.m. ET
November 07, 2014 08:00 ET | Capricor Therapeutics, Inc.
LOS ANGELES, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...